Fig. 6
From: PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
Overall survival curves of KMT2A positive patients in TARGET AML 1031 and AML 0531. A Odds ratio of the top enriched Cmap names and mechanisms of action (MOAs) identified through EFS Coxph regression analysis. B Overall survival curves of KMT2A fusion positive patients in TARGET AML 1031 (N = 220). Patients are classified by the ssGSEA score derived from genes affected by the HDAC inhibitor Vorinostat. C Overall survival curves of KMT2A fusion positive patients in TARGET AML 0531 (N = 46) validation cohort. Patients are classified by the ssGSEA score derived from genes affected by the HDAC inhibitor Vorinostat. D Cell-line sensitivity ranking based on IC50 values of Vorinostat. E Overall survival curves of KMT2A positive patients in TARGET AML 1031. Patients are classified by the ssGSEA score derived from genes affected by the ATPase inhibitor Thapsigargin. F Overall survival curves of KMT2A positive patients in TARGET AML 0531 validation cohort. Patients are classified by the ssGSEA score derived from genes affected by the ATPase inhibitor Thapsigargin. G Cell-line sensitivity ranking based on IC50 values of Thapsigargin